pre-IPO PHARMA

COMPANY OVERVIEW

Theraclone Sciences is a discovery-stage biotech developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. Their proprietary discovery platform allows them to comprehensively screen and identify the rare antibodies that select individuals produce to successfully ward off disease.


LOCATION

  • Seattle, WA, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Oncology

  • WEBSITE

    https://www.theraclone-sciences.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments amgen-ventures arch-venture-partners canaan-partners healthcare-ventures mpm-capital versant-ventures zenyaku-kogyo


    PRESS RELEASES


    Apr 30, 2015

    Theraclone Sciences' I-STAR™ Technology Chosen by Wellcome Trust to Identify Therapeutic Antibodies Against Ebola Virus


    Apr 24, 2014

    Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies Discovered with Theraclone Technology


    Dec 2, 2013

    PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences


    Nov 4, 2013

    Theraclone Sciences’ Monoclonal Antibody Candidate PGT121 Suppresses HIV in Simian Models of Disease


    Sep 11, 2013

    Theraclone Sciences Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013


    For More Press Releases


    Google Analytics Alternative